Entering text into the input field will update the search result below

Oramed's phase 2 trial of oral insulin candidate to reduce liver fat meets main goal

Sep. 13, 2022 11:27 AM ETOramed Pharmaceuticals Inc. (ORMP) StockBy: Anuron Mitra, SA News Editor

Liver disease.

Tharakorn/iStock via Getty Images

  • Oramed Pharmaceuticals (NASDAQ:ORMP) on Tuesday said a phase 2 trial assessing its oral insulin candidate to reduce liver fat content in type 2 diabetes patients with liver disease non-alcoholic steatohepatitis (NASH) met its main goal.

Recommended For You

More Trending News

About ORMP Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ORMP--
Oramed Pharmaceuticals Inc.